Emerging optical techniques in advanced cystoscopy for bladder cancer diagnosis: A review of the current literature

Cauberg Evelyne C.C., de la Rosette Jean J.M.C.H, de Reijke Theo M.
Department of Urology, Academic Medical Center, Amsterdam, the Netherlands

ABSTRACT

Background and objective: The current standard for the diagnosis and followup of bladder cancer remains white light cystoscopy, despite its well-known limitations. The aim of this paper is to review the current literature on three optical diagnostics that have been developed to improve the performance of white light cystoscopy: photodynamic diagnosis, narrow-band imaging and optical coherence tomography.

Materials and Methods: A PubMed search was performed for all articles on bladder cancer and photodynamic diagnosis, narrow-band imaging, and optical coherence tomography. Relevant papers on the working mechanism or clinical performance of the techniques were selected.

Results: Photodynamic diagnosis and narrow-band imaging both aim to improve the visualization of bladder cancer. Both techniques have demonstrated an improved detection rate of bladder cancer. For photodynamic diagnosis, decreased residual tumor rates and increased recurrence free survival after photodynamic diagnosis-assisted transurethral resection have been shown. Both techniques have a relatively high false positive rate. Optical coherence tomography is a technique aiming at real-time noninvasive pathological diagnosis. Studies have shown that optical coherence tomography can accurately discriminate bladder cancer from normal bladder mucosa, and even suggest that a reliable estimation of the stage of a bladder tumor can be made.

Conclusions: Photodynamic diagnosis is the technique with most evidence of clinical effectiveness to date, but low specificity is limiting a widespread use. For the novelties, narrow-band imaging, and optical coherence tomography, more evidence is needed before these techniques can be implemented in daily urological practice.

Key words: Diagnosis, fluorescence cystoscopy, imaging, narrow-band imaging, nonmuscle invasive bladder cancer, optical coherence tomography, photodynamic diagnosis, urothelial carcinoma

INTRODUCTION

Worldwide, about 357,000 of new bladder cancer cases are being diagnosed each year, which makes bladder cancer the 7th most common cancer in males and the 17th most common cancer in females.[1] Approximately 75% of patients present with non-muscle invasive disease and, therefore, have a relatively good prognosis in terms of cancer-specific survival. However, in up to 75% of these patients the cancer will recur despite transurethral resection (TUR) and adjuvant intravesical instillations with either chemotherapy or immunotherapy.[2] Because of this high recurrence rate, lifelong follow-up with cystoscopy and cytology and often repeated treatments are required, which make bladder cancer one of the most expensive cancers of today’s medical practice.[3]

In several fields efforts have been made to improve the management of these patients.

First, the role of bladder cancer screening has been studied extensively. The goal of screening, which is mainly based on hematuria detection by dipstick tests, is to identify the disease in an earlier stage in order to improve the chance of favorable outcome. However, to date there is no evidence that screening does achieve this goal, nor in which population the screening should take place and with what test.[3] In addition, many studies have been conducted on
Despite the introduction of these new modalities, the current standard for initial diagnosis as well as followup remains the direct visualization of the bladder mucosa by cystoscopy.

STILL THE DIAGNOSTIC STANDARD: WHITE LIGHT CYSTOSCOPY

Cystoscopy is an ancient technique that was first attempted in 1806 by Philipp Bozzini.[8] His “Lichtleiter” was composed of aluminum tubes with several angled mirrors to project the internal image to the human eye and a single candle to serve as a light source.[8] Since this first prototype, many advancements have been made, among which are the development of resectoscopes, video cameras, charge-coupled devices (CCDs), and flexible scopes.[9]

Although operator-dependent, the sensitivity and specificity of white light cystoscopy range from 62-84% and 43-98%, respectively.[10] Especially the detection of small papillary bladder tumors and satellite lesions as well as carcinoma in situ (CIS) is known to be suboptimal with white light cystoscopy.[10] This is expressed in the high early recurrence rate after TUR,[11] because “what the eyes cannot see, the hands cannot resect.” In order to decrease the number of tumors that are overlooked or not completely resected during TUR, it is important to improve the endoscopic visualization of bladder tumors.

Once a tumor has been detected by white light cystoscopy, it can be difficult to accurately predict the stage or grade based on its visual appearance.[12] Nevertheless, many urologists nowadays will opt for surveillance once a small papillary tumor recurs in a patient with a history of low grade, nonmuscle invasive bladder cancer (NMIBC).[13] In order to increase the safety of this strategy (i.e., not to defer active treatment of high grade or invasive lesions), it is desirable to have some kind of real-time pathological information during cystoscopy. The same goes for laser fulguration of bladder tumors, where no pathological confirmation is available due to lack of tissue specimen. In addition, real-time pathological information is desired to discriminate between inflammatory lesions due to previous instillation therapy and CIS, which both can present as red lesions.

While white light cystoscopy remains the current standard for diagnosis and followup, further improvements of the technique are clearly needed. The aim of the following review is to provide a timely overview of three relatively new optical techniques that have been introduced to advance endoscopy either by improving visualization of bladder tumors or by providing real-time pathological information.

MATERIALS AND METHODS

A literature search by PubMed was performed to retrieve all published articles on photodynamic diagnosis, narrow-band imaging, and optical coherence tomography as a diagnostic tool for bladder cancer. We used the search terms “bladder cancer” and “optical coherence tomography” or “photodynamic diagnosis” or “fluorescence cystoscopy” or “narrow-band imaging.” Papers written in English and concerning clinical evidence of the technique or explanation of working mechanism were selected. Reference lists of retrieved papers were scrutinized for additional relevant articles. Throughout the paper, the strength of the evidence on which the statements in the review are based is expressed in a narrative fashion.

EMERGING TECHNIQUES IN ADVANCED CYSTOSCOPY

Photodynamic diagnosis

Photodynamic diagnosis or fluorescence cystoscopy aims to improve the visualization of bladder cancer based on cystoscopic detection of fluorescent signals from neoplastic tissue. This fluorescence is accomplished by the intravesical administration of photosensitizing agents (5-aminolevulenic acid (5-ALA) or its derivative hexaminoethylinate (HAL)) which cause selective accumulation of photoactive porphyrins in rapidly proliferating cells (e.g., tumor cells). The solution containing the photosensitizing agents is instilled in the bladder via a transurethral catheter prior to surgery. The timing of instillation depends on the type of agent used: approximately 1 hour before surgery for HAL versus approximately 2-3 hours for 5-ALA. By illuminating the mucosa with blue-violet light, the neoplastic cells appear red or pink against a blue background [Figure 1].[10] Multiple studies have demonstrated that photodynamic diagnosis, in addition to white light cystoscopy, improves the detection of bladder cancer, for both papillary lesions
and CIS. A recent meta-analysis, which comprised 12 prospective trials, revealed that the overall additional detection rate of photodynamic diagnosis was 20% (range 5-49%). If specified for CIS only (seven trials), this was 39% (range 17-78%). However, the false-positive detection rate of photodynamic diagnosis was also higher if compared to white light cystoscopy (8.8-62.5% vs. 7.1-47%, respectively). False-positive fluorescence can be induced by inflammation, recent TUR, or tangential illumination of the bladder mucosa. False-positives will also occur more frequently in patients who recently have had intravesical therapy, especially bacillus Calmette-Guérin. Whether the improved detection also results in more complete resection can be examined by assessing the residual tumor rate at second resection up to 6 weeks after the initial photodynamic diagnosis-assisted TUR. In the meta-analysis, the average residual tumor rate for white light-TUR and photodynamic diagnosis-assisted TUR was 35% and 15%, respectively (OR 0.28). The positive effect of photodynamic diagnosis on therapeutic outcome was also demonstrated in a recent randomized, multicenter phase 3 study: the recurrence rate at 9 months was statistically significantly reduced with 10% for HAL-assisted TUR. These results were confirmed by a longer recurrence-free survival if compared to white light TUR: 15.8-27% higher at 12 months and 12-15% higher at 24 months. This difference seems to extend on the longer term (over 5 years). Photodynamic diagnosis has a good safety profile: only mild to moderate adverse events may occur after instillation. Based on the decreased recurrence rate of photodynamic diagnosis-assisted TUR and consequently decreased need for re-TUR, one can hypothesize that this technique will have a positive effect on health care costs. Only few model-based analyses have investigated the cost-effectiveness of photodynamic diagnosis assisted TUR to date. Two studies suggest that the technique indeed reduces the overall expenses, when taking into account the acquisition and usage costs of the photodynamic diagnosis system. However, these studies are derived from 5-ALA data only and based on German health economics, which may hamper extrapolation of the outcome. In a very recent extensive systematic review from the United Kingdom, the cost-effectiveness of photodynamic diagnosis was only borderline.

In summary, photodynamic diagnosis improves detection of NMIBC and photodynamic diagnosis-assisted TUR decreases residual tumor rate and seems to increase recurrence-free survival. The relatively high false-positive rate is the major limitation to date. More multi-institutional studies are needed to confirm the additive value of photodynamic diagnosis on the long-term and to further evaluate its cost-effectiveness.

**Narrow-band imaging**

Narrow-band imaging is a straightforward optical technique designed for endoscopy to enhance the visualization of (sub) mucosal vessels. The working mechanism is based on the filtering of white light into two narrow bandwidths of light that are centered around 415 nm (blue light) and 540 nm (green light), which penetrate tissue only superficially and are specifically absorbed by hemoglobin. Because bladder tumors tend to be well vascularised, narrow-band imaging will increase the contrast between these lesions and normal bladder mucosa.

In 2007, Bryan et al. were the first to describe the additive value of narrow-band imaging in flexible cystoscopy performed on 29 patients in followup for NMIBC. In 12 (41%) patients, 15 additional lesions were detected by narrow-band imaging only. Although these lesions appeared to be malignant, histopathological confirmation was not available. Since this preliminary report, four studies have been published on the value of narrow-band imaging cystoscopy for the detection of NMIBC. Although the studies had a different set-up (flexible vs. rigid cystoscopy, etc.) and different patient population (outpatient followup vs. scheduled for TUR, etc.), all showed improved bladder cancer detection for narrow-band imaging over white light cystoscopy. Based on the data provided in the manuscripts, we calculated the additional detection rate of narrow-band imaging (over white light cystoscopy) to range from 17% to 31%. Overall, in 22–56% of NMIBC patients narrow-band imaging detected additional tumors. It has to be noted that in the studies of Herr et al. and Naselli et al. white light cystoscopy and subsequent narrow-band imaging cystoscopy were performed by the same urologist, which may introduce some observational bias, as is acknowledged by the authors. However, the improved detection rate of

**Figure 1:** Small pTaG2 bladder tumor, increased visibility with photodynamic diagnosis (right) versus white light cystoscopy (left).

**Figure 2:** Field of pTaG2 bladder tumor, increased visibility with narrow-band imaging (right) versus white light cystoscopy (left).
narrow-band imaging was also demonstrated in the study conducted by the authors of this review where white light cystoscopy and narrow-band imaging cystoscopy were performed independently by various urologists.\cite{31,32} The reported false-positive rates ranged from 32% to 36%.\cite{33,34} Besides this relatively high false-positive rate, another limitation of this technique was noted by two groups: in case of severe hematuria, visualization is suboptimal because of the absorption of the narrow-band imaging light by circulating erythrocytes.\cite{31,32} Herr et al. also performed a study on the interobserver variability of narrow-band imaging cystoscopy. Captured images of narrow-band imaging cystoscopy performed on 50 patients on followup for NMIBC were independently reviewed by four urologists. All observers performed equally, suggesting that there is no learning curve for narrow-band imaging.\cite{35}

In summary, to date only a few studies with relatively small patient numbers have been conducted on the value of narrow-band imaging for the detection of bladder cancer. Nevertheless, the results of these series are very promising and collectively indicate improved detection of NMIBC, though with relatively high number of false-positives. The major advantage of narrow-band imaging is the fact that no intravesical agent is needed before application. Further prospective, preferably randomized, comparative studies need to be conducted to prove these initial results.

Importantly, future research should also focus on the effect of narrow-band imaging on residual tumor rate and recurrence-free survival as well as cost-effectiveness of the technique.

**Optical coherence tomography**

Optical coherence tomography is a noninvasive optical technique that can provide cross-sectional images containing subsurface tissue information. It is the optical equivalent of B-mode ultrasound imaging, except that it is based on depth-resolved detection of backscattered light instead of reflected sound waves. This results in images with a high resolution of up to 2 µm (approaching the resolution of microscopy) and a maximum imaging depth of 2–3 mm.\cite{36} Because optical coherence tomography does not require a medium or direct contact with the tissue under investigation; it is well suitable for endoscopic applications (by inserting a (flexible) optical coherence tomography probe through the working channel of a cystoscope) [Figure 3].\cite{37}

Over the last decade, several studies have been conducted on the ability of optical coherence tomography to detect bladder cancer, both ex vivo\cite{38,40} and in vivo (e.g., endoscopically).\cite{41-45} These studies have shown that it is feasible to distinguish the different bladder wall layers including lamina propria and muscularis propria with optical coherence tomography.\cite{38,40,46} Furthermore, optical coherence tomography can differentiate urothelial carcinoma (UC) from normal bladder mucosa with a sensitivity and specificity ranging from 84% to 100% and from 78% to 90%, respectively.\cite{40,41,44,45} The discrimination of normal urothelium versus UC is based on qualitative analysis of the optical coherence tomography images: in normal tissue, the urothelium is uniform and the bladder wall layers are clearly delineated based on their different backscattering capacities, whereas UC shows increased backscattering, heterogeneity, and broadened urothelium in case of papillary tumors.\cite{38,40,43,47} Two groups demonstrated that optical coherence tomography also has the power to determine the stage of a detected UC. Lerner et al. demonstrated that optical coherence tomography could discriminate Ta, T1, and T2 tumors with a sensitivity of 90%, 75%, and 100%, respectively and a specificity of 89%, 97%, and 90%, respectively. The group of Zagaynova et al. evaluated 28 cases with optical coherence tomography during TUR and discrimination between muscle-invasive and nonmuscle-invasive tumors could be done with a sensitivity of 100% and specificity of 77%.\cite{48} Although the studies on optical coherence tomography as a bladder cancer diagnostic appear very promising, the technique does have some limitations that need to be addressed. False-positives may be induced by scarring\cite{45} or inflammation of the mucosa.\cite{44} In general, for large tumors with extensive broadened urothelium imaging depth will be impaired, thus compromising the staging ability of optical coherence tomography.\cite{45} However, Zagaynova et al. have shown that this problem may be overcome by applying optical
coherence tomography to the tumor base. In addition, the technique is not very suitable for bladder mapping because of its limited field of view.

In summary, optical coherence tomography is a noninvasive optical technique that can provide in-depth tissue information. Although the first studies indicate the capability of optical coherence tomography to discriminate UC from normal mucosa and even to give some stage information, more clinical series are needed to confirm these promising results. Special attention should be given to the potential of optical coherence tomography to diagnose CIS, since this highly aggressive disease is difficult to detect with white light cystoscopy. In addition, the effect of prior intravesical therapy on the specificity of optical coherence tomography should be examined.

**DISCUSSION**

The three optical techniques discussed above all have their strengths and weaknesses. However, they also have different goals: whereas photodynamic diagnosis and narrow-band imaging both focus on improvement of the visualization of bladder tumors, optical coherence tomography focuses on real-time pathological diagnosis. Narrow-band imaging and photodynamic diagnosis both can aid in reducing the high rate of early recurrences, because more radical resection can be performed due to better visualization of UC. In addition, in case of positive cytology and negative white light cystoscopy, photodynamic diagnosis (and perhaps also narrow-band imaging) can improve detection of CIS. Optical coherence tomography may possibly assist in differentiation between inflammation and CIS, which both can present as red lesions. It may also aid in accomplishing a more complete resection, by measuring the resection margins with optical coherence tomography and extending resection if vital tumor is still present. In addition, optical coherence tomography may provide pathological diagnosis for the patients with recurrent tumors under followup or before laser treatment.

As mentioned above, all three techniques discussed in this review may aid in accomplishing a more complete resection of bladder cancer. In theory, this consequently will result in lower residual tumor rates and also in longer recurrence-free survival, as already has been proven for photodynamic diagnosis. One can hypothesize that the effect of these techniques may render adjuvant intravesical instillations that aim at reducing recurrences redundant. This is now being evaluated in an international prospective trial randomizing patients to white light-TUR with adjuvant intravesical therapy or photodynamic diagnosis assisted TUR without adjuvant intravesical therapy (HELENA protocol, personal communications, 26-04-2010, Th.M. de Reijke).

When comparing the two visualization techniques, detection rates and false-positive rates seem to be comparable, but photodynamic diagnosis is more established with stronger supporting evidence so far. Photodynamic diagnosis has been recommended in the European guidelines for the detection of CIS. In addition, the contrast provided with this technique seems more apparent than with narrow-band imaging. However, given the practical disadvantages of photodynamic diagnosis (need for intravesical instillation of fluorescent agent and high costs), narrow-band imaging may be a valid alternative for the detection of NMIBC. Because narrow-band imaging does not rely on intravesical instillation of fluorescent agents, the technique is also well suitable for use in the outpatient clinic.

In future, one may consider combining some of these optical techniques so that the strengths of one technique can be used to overcome the limitations of the other. For example, the combination of photodynamic diagnosis and optical coherence tomography in an animal study led to increased specificity of diagnosing UC in rat bladders. These results were also shown in human studies that combined photodynamic diagnosis with optical coherence tomography: in one study on 26 patients with suspicion of UC, the false-positive rate of photodynamic diagnosis only (84%) could be decreased (78.7%) by adding optical coherence tomography. In other words, the 16% positive predictive value of photodynamic diagnosis increased to 43% if combined with optical coherence tomography. Recently, Schmidbauer et al. showed that adding optical coherence tomography to photodynamic diagnosis increased the overall diagnostic accuracy: sensitivity and specificity were respectively 69.3% and 83.7% for white light cystoscopy, 97.5% and 78.6% for photodynamic diagnosis, and 97.5% and 97.9% for photodynamic diagnosis combined with optical coherence tomography. These results suggest that combining optical coherence tomography with photodynamic diagnosis can reduce the number of unnecessary false-positive biopsies. To our knowledge, no studies on the combination of narrow-band imaging and optical coherence tomography have been published yet.

Optical coherence tomography and narrow-band imaging may also be applied as diagnostics in the upper tract in future. For photodynamic diagnosis, it seems that this is not feasible due to problems with instillation of the fluorescent agent and inevitable tangential illumination in the ureter causing false-positivity. Narrow-band imaging is not hampered by tangential light beams nor requires fluorescent agents and, therefore, may improve the detection of CIS or small papillary lesions, which can be easily missed by conventional imaging studies of the upper tract (retrograde studies, IVP or CT). Optical coherence tomography may overcome the limitations encountered in upper tract biopsies, which tend to have a high rate of nondiagnostics due to insufficient or low-quality specimen. By applying optical
coherence tomography measurements of an upper tract lesion before taking a biopsy (or even replacing biopsy), the diagnostic accuracy may be increased. These days, a correct pretreatment stage and grade is becoming quite essential because more and more upper tract tumors are being treated endoscopically and organ-sparing.

REFERENCES

1. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56:430-2.

2. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffieux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-475.

3. Madeb R, Golijanin D, Knopf JJ, Messing EM. Current state of screening for bladder cancer. Expert Rev Anticancer Ther 2007;7:981-7.

4. Lokeshvar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001;165:1067-77.

5. Lokeshvar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66:35-63.

6. Kivrik AS, Kiresi D, Emlik D, Odev K, Kilinc M. Comparison of CT virtual cystoscopy of the contrast material-filled bladder with conventional cystoscopy in the diagnosis of bladder tumours. Clin Radiol 2009;64:30-7.

7. Koplay M, Kantarci M, Guven F, Aksoy Y, Taser F, Ziyak T, et al. Diagnostic efficiency of multidetector computed tomography with multiplanar reformatted imaging and virtual cystoscopy in the assessment of bladder tumors after transurethral resection. J Comput Assist Tomogr 2010;34:121-6.

8. Bush RB, Leonhardt H, Bush IV, Landes RR, Dr. Bozzini’s Lichtleiter. A translation of his original article (1806). Urology 1974;3:119-23.

9. Nataf RA, Landman J. Where next for the endoscope? Nat Rev Urol 2009;6:622-8.

10. Jochem D, Stepp H, Waidelich R. Photodynamic Diagnosis in Urology: State-of-the-Art. Eur Urol 2008;53:1138-50.

11. Brausi M, Collette L, Kivrik AS, Kiresi D, Emlik D, Odev K, Kilinc M. Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol 2001;32:630-7.

12. Soloway MS. Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. Urol Oncol 2006;24:58-61.

13. Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, Oberneder M, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001;57:690-4.

14. Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007;69:260-4.

15. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-7.

16. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:68-73.

17. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-8.

18. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies. Eur Urol 2010;57:595-606.

19. Grimbergen MC, van Swol CF, Jonge TG, Boon TA, van Moorselaar R. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003;44:51-6.

20. Draga RO, Grimbergen MC, Kok ET, Jonge TN, van Swol CF, Bosch JL. Photodynamic Diagnosis (5-Aminolevulinic Acid) of Transitional Cell Carcinoma After Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Intravesical Therapy. Eur Urol 2010;57:655-60.

21. Mynderse LM, Rochester MN, Stenzl A, Denzinger S, Fradet Y, Soloway MS, et al. Hexaminolevulinate fluorescence cystoscopy improves detection and resection of papillary bladder cancer lesions and reduces early recurrences. 2009.

22. Denzinger S, Burger M, Walter B, Kneuehler C, Roessler W, Wieland W, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007;69:675-9.

23. Danilchenko DJ, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005;174:2129-33.

24. Burger M, Zaak D, Stief CG, Filbeck T, Wieland WF, Roessler W, et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 2007;52:142-7.

25. Mowatt G, Zhu S, Kilonzso M, Boachie C, Fraser C, Griffiths TR, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010;14:1-4.

26. Zaak D, Wieland WF, Stief C, Burger M. Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic Issues. European Urology supplements 2008;7:536-41.

27. Kuznetsov K, Lambert R, Rey JF. Narrow-band imaging: potential and limitations. Endoscopy 2006;38:76-81.

28. Song LM, Adler DG, Conway JD, Diehl DL, Farraye FA, Kantsevoy SV, et al. Narrow band imaging and multiband imaging. Gastrointest Endosc 2008;67:581-9.

29. Bryan RT, Bilingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int 2008;101:702-05.

30. Cauberg EC, Klen S, Visser M, de la Rosette JJ, Babjuk M, Solsona E, et al. Narrow Band Imaging Cystoscopy Improves the Detection of Non-muscle-invasive Bladder Cancer. Urology 2010;76:658-63.

31. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008;102:1111-4.

32. Herr HW. Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guerin therapy: preliminary results. BJU Int 2010;105:314-6.

33. Naselli A, Introro C, Bertolotto F, Spina B, Puppo P. Narrow band imaging for detecting residual/recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer. BJU Int 2010;105:208-11.

34. Herr H, Donat M, Dalbagni G, Taylor J. Narrow-band imaging cystoscopy
to evaluate bladder tumours - individual surgeon variability. BJU Int 2010;106:53-5.

36. Zyshk AM, Nguyen FT, Oldenburg AL, Marks DL, Boppart SA. Optical coherence tomography: A review of clinical development from bench to bedside. J Biomed Opt 2007;12:051403.

37. Sergeev A, Gelikonov V, Gelikonov G, Feldchtein F, Kuranov R, Gladkova N, et al. In vivo endoscopic OCT imaging of precancer and cancer states of human mucosa. Opt Express 1997;1:432-40.

38. Jesser CA, Boppart SA, Pitriss C, Stamper DL, Nielsen GP, Brezinski ME, et al. High resolution imaging of transitional cell carcinoma with optical coherence tomography: feasibility for the evaluation of bladder pathology. Br J Radiol 1999;72:1170-6.

39. Lingley-Papadopoulos CA, Loew MH, Manyak MJ, Zara JM. Computer recognition of cancer in the urinary bladder using optical coherence tomography and texture analysis. J Biomed Opt 2008;13:024003.

40. Hermes B, Spoler F, Naami A, Bornemann J, Forst M, Grosse J, et al. Visualization of the basement membrane zone of the bladder by optical coherence tomography: feasibility of noninvasive evaluation of tumor invasion. Urology 2008;72:677-81.

41. Manyak MJ, Gladkova ND, Makari JH, Schwartz AM, Zagaynova EV, Zolfaghari L, et al. Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. J Endourol 2005;19:570-4.

42. Zagaynova EV, Streitsov AS, Gladkova ND, Snopova LB, Gelikonov GV, Feldchtein FI, Morozov AN. In vivo optical coherence tomography feasibility for bladder disease. J Urol 2002;167:1492-6.

43. Wang Z, Lee CS, Waltzer WC, Liu J, Xie H, Yuan Z, Pan Y. In vivo bladder imaging with microelectromechanical-systems-based endoscopic spectral domain optical coherence tomography. J Biomed Opt 2007;12:034009.

44. Lerner SP, Goh AC, Tresser NJ, Shen SS. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 2008;72:133-7.

45. Ren H, Waltzer WC, Bhalia R, Liu J, Yuan Z, Lee CS, et al. Diagnosis of bladder cancer with microelectromechanical-systems-based cystoscopic optical coherence tomography. Urology 2009;74:1351-7.

46. Tearney GJ, Brezinski ME, Southern JF, Bouna BE, Boppart SA, Fujimoto JG. Optical biopsy in human urologic tissue using optical coherence tomography. J Urol 1997;157:1915-9.

47. Pan Y, Lavelle JP, Bastacky SI, Meyers S, Pirskhaladshvili G, Zeidel ML, et al. Detection of tumorigenesis in rat bladders with optical coherence tomography. Med Phys 2001;28:2432-40.

48. Zagaynova E, Gladkova N, Shakhova N, Gelikonov G, Gelikonov V. Endoscopic OCT with forward-looking probe: clinical studies in urology and gastroenterology. J Biophotonics 2008;1:114-28.

49. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303-14.

50. Wang ZG, Durand DB, Schoenberg M, Pan YT. Fluorescence guided optical coherence tomography for the diagnosis of early bladder cancer in a rat model. J Urol 2005;174:2376-81.

51. Schmidbauer J, Remzi M, Klatte T, Waldert M, Mauerma J, Susani M, et al. Fluorescence Cystoscopy with High-Resolution Optical Coherence Tomography Imaging as an Adjunct Reduces False-Positive Findings in the Diagnosis of Urothelial Carcinoma of the Bladder. Eur Urol 2009;56:914-9.